- While 2024 earnings growth will be driven by improvements in Raffles Medical (SGX:BSL)’s Singapore operations and lower losses from its China unit, longer-term earnings will be driven by its China operations, which are a few years away from breaking even in EBITDA terms.
- - Read this at SGinvestors.io -
- We see risks of higher operating costs amidst a tight labour market for skilled healthcare workers, a still-low foreign patient load, and losses from the health insurance unit.
Acknowledgement of increased regional competition.
- At its latest AGM, Raffles Medical acknowledged, in response to shareholders’ questions, that the appreciation of the S$ vs regional currencies has impacted Singapore's position as a medical hub, as it enabled certain healthcare service providers in neighbouring countries to take advantage of this situation.
- - Read this at SGinvestors.io -
Chairman has been increasing his stake in Raffles Medical.
- Read more at SGinvestors.io.
Shekhar Jaiswal RHB Securities Research | https://www.rhbgroup.com/ 2024-06-05
Read also RHB's most recent report:
2024-07-01 Raffles Medical - Lukewarm Investor Response.
Price targets by other brokers at Raffles Medical Target Prices.
Listing of research reports at Raffles Medical Analyst Reports.
Relevant links:
Raffles Medical Share Price History,
Raffles Medical Announcements,
Raffles Medical Dividends & Corporate Actions,
Raffles Medical News Articles
